Biomarin Pharmaceutical Inc

Most Recent

  • uploads///valuation catalysts in H
    Company & Industry Overviews

    Inside BioMarin’s Big Plans for 3Q16

    BioMarin decided to withdraw its MAA (Marketing Authorization Application), given the expectation of a negative decision on the drug from the EMA.

    By Jillian Dabney
  • uploads///Exon skipping
    Earnings Report

    BioMarin Has Suffered from Kyndrisa’s Rejection

    The recent fall in BioMarin’s stock price is due to the rejection of its drug Kyndrisa, indicated for Duchenne muscular dystrophy.

    By Jillian Dabney
  • uploads///TSRO
    Company & Industry Overviews

    Gauging Analysts’ Views on Tesaro Stock

    In November, of the total 21 analysts covering Tesaro (TSRO) stock, 13 have given it “buy” or higher ratings, and eight have given it “hold” ratings.

    By Kenneth Smith
  • uploads///BioMarin performance projections
    Company & Industry Overviews

    What to Expect from BioMarin Pharmaceuticals in 2017

    In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).

    By Daniel Collins
  • uploads///Spark ana reco
    Company & Industry Overviews

    What Spark Therapeutics’ Valuation Trend Indicates

    Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.

    By Kenneth Smith
  • uploads///BMRN
    Company & Industry Overviews

    How BioMarin Pharmaceutical Is Positioned Financially in August

    In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.

    By Daniel Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI’s Large Caps: BioMarin Gives Update on Gene Therapy Study

    The large-cap stocks of the SPDR S&P Biotech ETF (XBI) rose 0.3% on April 20, 2016. Large-cap stocks account for 19.3% of XBI’s portfolio.

    By Peter Neil
  • uploads///revenue projections
    Company & Industry Overviews

    What’s BioMarin’s Expected Revenue Growth in 2016 and 2017?

    During its 2Q16 earnings call, BioMarin revised its 2016 revenue guidance. It now expects revenue to be $1.1 billion–$1.15 billion.

    By Jillian Dabney
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Europe Approved Biogen’s Elocta, Topped XBI’s Large-Cap Stocks

    Biogen rose 1% on November 25. It closed at $292.30. It was trading 5.7% below the 100-day moving average price of $309.85. It passed the 20-day moving average.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Incyte Guidance on Jakafi Sends Stock High

    On May 23, 2016, Incyte (INCY) was the biggest gainer among the large-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) with a gain of 3.9%.

    By Peter Neil
  • uploads///revenue projections
    Company & Industry Overviews

    BioMarin to Cross $1 Billion Revenue in 2016

    BioMarin Pharmaceutical (BMRN) expects its existing commercialized drugs to add $1.1 billion and $1.2 billion to its top line in 2016.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    How Does XBI Compare to Its 100-Day Moving Average?

    The SPDR S&P Biotech ETF (XBI) rose marginally by 0.1% on April 20, 2016. Within XBI, Kite Pharma (KITE) closed at $48.98 on the day.

    By Peter Neil
  • uploads///ANR
    Earnings Report

    BioMarin: Why So Many ‘Buy’ Recommendations?

    BioMarin (BMRN) is expected to report 2Q16 earnings on August 4, 2016. “Buy” ratings have increased to 94.7% from 90% on June 29, 2016.

    By Jillian Dabney
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Amgen Rises by 2% as XBI’s Large-Cap Stocks Rally

    Amgen closed at $157.60 and was trading above its 50- and 100-day moving averages. The stock also witnessed a rise in trading volumes.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Alexion Continues to Rise on FDA’s Approval of Kanuma

    Alexion Pharmaceuticals (ALXN) gained 2.5% on December 10, 2015. The stock went up after the FDA (Food and Drug Administration) approved its drug, Kanuma.

    By Peter Neil
  • uploads///sales Q segmentwise
    Earnings Report

    How Did Novo’s 2 Segments Perform in 1Q16?

    Novo Nordisk’s two business segments are diabetes and obesity care and biopharmaceuticals. In 1Q16, they saw annual sales growth of 6% and 15%, respectively.

    By Jillian Dabney
  • uploads///krystexxa
    Company & Industry Overviews

    Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug

    Horizon plans to drive Krystexxa through increased awareness and outreach, investing in its marketing and medical education as well as commercial infrastructure.

    By Jillian Dabney
  • uploads///BioMarin Timeline
    Company & Industry Overviews

    Overview of BioMarin: History and Product Portfolio

    Here we present an overview of BioMarin. It’s based in California and was founded in 1997. It focuses on therapies for life-threatening rare genetic diseases.

    By Jillian Dabney
  • uploads///hands _
    Healthcare

    Novartis Enters Agreement to Acquire AveXis

    On April 9, 2018, Novartis AG announced that it had entered into an agreement to acquire AveXis for ~$8.7 billion.

    By Mike Benson
  • uploads///revue ee
    Earnings Report

    BioMarin’s Disappointing 3Q16 Earnings

    BioMarin Pharmaceutical (BMRN) reported its 3Q16 earnings on October 27, 2016. Revenues were $279.9 million, which was lower than Wall Street analysts’ projections.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    Endo International Market Cap Fell: Reduced to Mid-Cap

    Endo International (ENDP) announced its 4Q15 earnings on February 29, 2016. Its 4Q15 revenue was $1,074 million, and it reported a diluted earnings per share of $1.97.

    By Peter Neil
  • uploads///hemophilia market size
    Company & Industry Overviews

    Could Baxalta Maintain Its Leadership in the Hemophilia Space?

    Baxalta’s (BXLT) hemophilia portfolio comprises of Advate, Adynovate, Rixubis, Recombinate, Hemofil M, Immunate, Immunine, and Prothromplex Total.

    By Jillian Dabney
  • uploads///Graph Autosomal recessive pattern
    Company & Industry Overviews

    BioMarin Leads in the Market for Mucopolysaccharidoses Disorders

    BioMarin holds three drugs in its portfolio indicated for different types of mucopolysaccharidoses disorders. They are Vimizim, Naglazyme, and Aldurazyme.

    By Jillian Dabney
  • uploads///Graph pipeline
    Company & Industry Overviews

    BMN 270: A Big Valuation Catalyst for BioMarin

    On March 1, 2016, BioMarin received orphan drug designation for BMN 270 from the FDA. BioMarin’s stock jumped by about 6.96% the same day.

    By Jillian Dabney
  • uploads///human geentics therapies
    Earnings Report

    What to Expect from Shire’s Genetic Disease Franchise

    Wall Street analysts expect Elaprase to earn $145.6 million in 2Q16 and $140.5 million in 3Q16.

    By Jillian Dabney
  • uploads///BioMarin Financial projections
    Earnings Report

    BioMarin: How Much Revenue Growth in 2Q16?

    According to analyst estimates, BioMarin should earn $278.4 million and $273.5 million in 2Q16 and 3Q16, respectively. That’s a yearly sales growth of 11.1% and 30.9%, respectively.

    By Jillian Dabney
  • uploads///Roche growth
    Company & Industry Overviews

    Why Roche Might Be Interested in BioMarin

    With increased M&A activity in the pharmaceuticals and biotechnology space, it wouldn’t be surprising if Roche Holding (RHHBY) acquired BioMarin (BMRN).

    By Jillian Dabney
  • uploads///chemist _
    Healthcare

    Why Sesen Bio Stock Jumped Over 37% this Week

    Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies. The stock jumped ~26.1% to $2.27 yesterday.

    By Mike Benson
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Agios Outperformed: Rose 24.8% and Helped IBB Gain 3.2%

    Agios Pharmaceuticals (AGIO) rose by a staggering 24.8% on October 27, 2015. It was the top performer in IBB’s portfolio.

    By Peter Neil
  • uploads///Alkermes
    Company & Industry Overviews

    How’s Alkermes Positioned Financially in September?

    In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    How Ionis’s Spinraza Performed in 3Q17

    Ionis Pharmaceuticals’ Spinraza is a drug designed for the treatment of spinal muscular atrophy (or SMA), a type of severe motor-neuron disease.

    By Mike Benson
  • uploads///lab _
    Earnings Report

    How Did Jazz Pharmaceuticals Perform in the Second Quarter?

    Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    Sangamo Therapeutics Rises on Positive Clinical Trial Results

    On Friday last week, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced promising updated results from their Phase 1/2 ALTA trial.

    By Margaret Patrick
  • uploads///biochemistry biology blue
    Company & Industry Overviews

    Horizon Therapeutics or BioMarin: Which Is a Better Bet in July?

    Horizon Therapeutics (HZNP) is up 23.13%, and BioMarin (BMRN) is down 6.62% year-to-date. Let’s study the drivers and risks for both these rare disease players in greater detail.

    By Margaret Patrick
  • uploads///SRPT EPS
    Company & Industry Overviews

    A Look at Sarepta Therapeutics’ Recent Developments

    In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.

    By Daniel Collins
  • uploads///SRPT
    Company & Industry Overviews

    How Is Sarepta Therapeutics Positioned in January?

    In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.

    By Daniel Collins
  • uploads///virus _
    Company & Industry Overviews

    Sarepta Therapeutics Stock Rose 96% in 2018

    On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.

    By Daniel Collins
  • uploads///SAGE
    Company & Industry Overviews

    Sage Therapeutics’ Operational Performance

    In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively.

    By Kenneth Smith
  • uploads///nerve cell _
    Company & Industry Overviews

    Sage Therapeutics: Analyzing New Product Candidates

    The Zulresso injection is Sage Therapeutics’ lead product candidate. The company has filed a new drug application.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    Why Neurocrine Biosciences Stock Is Plummeting Today

    Today, Neurocrine Biosciences (NBIX) is trading at $67.91, a ~20.83% fall from its closing price of $85.76 on December 11.

    By Daniel Collins
  • uploads///Biomarin
    Company & Industry Overviews

    How BioMarin Pharmaceutical’s Financials Look in November

    BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.

    By Daniel Collins
  • uploads///CLVS
    Company & Industry Overviews

    Gauging Analysts’ Views on Clovis Stock

    In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.

    By Kenneth Smith
  • uploads///dna _
    Earnings Report

    Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings

    Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Allergan’s Q3 2018 Estimates: Revenue Decline Expected

    Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decline 3.8% to $3.88 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Biogen: Analysts’ Recommendations on October 19

    For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Here Are the Key Products in Sage’s GABA Receptor Portfolio

    Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for Shire on September 19

    Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017.

    By Mike Benson
  • uploads///BMRN ana reco
    Company & Industry Overviews

    Analysts Remain Bullish on BioMarin Pharmaceutical

    Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in September, 19 of them have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    BioMarin Pharmaceutical and Its Promising Research Pipeline

    Stocks focused on gene therapy have garnered strong investor interest in 2018. In this series, we’ll analyze four of those companies.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for Bluebird Bio on September 6

    Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating investigational Lenti-D gene therapy.

    By Mike Benson
  • uploads///addiction _
    Company & Industry Overviews

    How Analysts View BioMarin Pharmaceutical in August

    On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Incyte’s Revenue Stream in Q2 2018

    Incyte (INCY) reported revenue of $521.5 million in the second quarter, a 59.7% rise YoY (year-over-year).

    By Mike Benson
  • uploads///TSRO
    Company & Industry Overviews

    Here’s What Tesaro’s Valuation Trend Indicates

    Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.

    By Kenneth Smith
  • uploads///microscope _
    Earnings Report

    Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

    Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.

    By Mike Benson
  • uploads///Jazz analysts
    Earnings Report

    Wall Street Analysts Are Mostly Positive on Jazz Pharmaceuticals

    Jazz Pharmaceuticals anticipates net revenues to be in the range of $1.88 million to $1.93 million in fiscal 2018.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    How Ionis’s Q2 2018 Earnings Trended

    Ionis reported 5% YoY growth in revenues to $117.7 million during Q2 2018 as compared to $112.3 million during the second quarter of 2017.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Bluebird Bio Misses Analysts’ Estimates in Q2 2018

    Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Recommend for Bluebird Bio Stock

    As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What to Expect from Shire’s Q2 2018 Earnings on July 31

    Shire (SHPG) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS of $3.67 on revenues of $3.8 billion.

    By Mike Benson
  • uploads///drug _
    Earnings Report

    Amgen Beats Estimates, Reports Growth in Q2 2018

    Amgen (AMGN) reported in Q2 2018 results yesterday, surpassing analysts’ EPS and revenue estimates.

    By Mike Benson
  • uploads///addiction _
    Earnings Report

    How Does BioMarin Pharmaceutical Look ahead of Its Q2 Earnings?

    BioMarin Pharmaceutical (BMRN) plans to release its Q2 2018 results on August 2. In Q1 2018, BMRN reported net revenues of $373.4 million.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Sage Therapeutics’ GABA Receptor–Based Products

    On June 12, Sage Therapeutics announced its expedited development plan for SAGE-217.

    By Mike Benson
  • uploads///feature
    Company & Industry Overviews

    Vivus Stock Rose 60% Last Week

    Vivus stock rose 60% between May 11 and May 18.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    How Analysts View BioMarin Pharmaceuticals and Peers in April

    Of the 23 analysts covering BioMarin Pharmaceuticals in April 2018, eight analysts gave the stock a “strong buy” rating.

    By Kenneth Smith
  • uploads///BMRN
    Company & Industry Overviews

    Cash Flows and Valuation Metrics of BioMarin Pharmaceuticals

    BioMarin Pharmaceuticals’ (BMRN) cash, cash equivalents, and investments increased from $1.3 billion in fiscal 2016 to $1.7 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///BMRN
    Company & Industry Overviews

    A Look at BioMarin Pharmaceuticals’ Therapy Portfolio

    In December 2017, BioMarin Pharmaceuticals (BMRN) sold a rare pediatric disease priority review voucher to Novartis (NVS) for $125.0 million.

    By Kenneth Smith
  • uploads///rawpixel com  unsplash
    Company & Industry Overviews

    How Analysts View Tetraphase Pharmaceuticals in April 2018

    Of eight analysts tracking Tetraphase Pharmaceuticals, one analyst rated it as a “strong buy,” and six analysts gave it a “buy” rating.

    By Kenneth Smith
  • uploads///cells _
    Company & Industry Overviews

    Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018

    Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations.

    By Kenneth Smith
  • uploads///Analysts
    Company & Industry Overviews

    Analysts’ Recommendations for BioMarin Pharmaceutical

    In March 2018, the EMA (European Medicines Agency) accepted BioMarin Pharmaceutical’s (BMRN) marketing authorization application for pegvaliase.

    By Daniel Collins
  • uploads///FI
    Company & Industry Overviews

    How BioMarin Pharmaceutical Performed in 4Q17 and 2017

    In 4Q17, BioMarin Pharmaceutical (BMRN) generated revenue of $358.3 million, compared with $300.1 million in 4Q16.

    By Daniel Collins
  • uploads///Chart
    Healthcare

    Ionis Pharmaceuticals’ Valuation as of March 27, 2018

    Wall Street analysts estimate that Ionis Pharmaceuticals (IONS) stock might increase 25.1% over the next 12 months.

    By Mike Benson
  • uploads///medic _
    Healthcare

    Ionis Pharmaceuticals Stock as of March 27, 2018

    Ionis Pharmaceuticals stock has fallen 6.9% over the last week. However, it rose 2.6% to close at $48.99 on March 26, 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Key Updates on Akcea Therapeutics’ Volanesorsen

    Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug for the treatment of familial chylomicronemia syndrome (or FCS) and familial partial lipodystrophy (or FPL).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis’s Key Revenue Drivers in 4Q17

    Ionis Pharmaceuticals (IONS) reported 7.5% growth in revenues to $172.3 million during 4Q17 as compared to revenues of $160.3 million during 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Did Ionis’s Revenues Trend in 4Q17?

    Ionis (IONS) is a leading biopharmaceutical company focused on discovering, developing, and commercializing RNA-targeted therapies.

    By Mike Benson
  • uploads///FD
    Company & Industry Overviews

    Alexion Pharmaceuticals in 4Q17 and Fiscal 2017

    In 4Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $910 million, which reflected ~10% growth on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Spinraza
    Company & Industry Overviews

    How Biogen’s Spinraza Is Positioned for 2018

    In 4Q17, Biogen’s (BIIB) Spinraza generated revenues of $363 million, which reflected 34% quarter-over-quarter growth.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis’s 3Q17 Revenue Stream

    Ionis Pharmaceuticals (IONS) reported a 9% rise in its revenue to $120.9 million in 3Q17 compared to $110.9 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Was Incyte’s Revenue Stream in 3Q17?

    Incyte’s total product royalty revenue was $44.5 million in 3Q17, a rise compared to $29.6 million in 3Q16.

    By Mike Benson
  • uploads///Chart  Rev
    Company & Industry Overviews

    Changes in Gilead’s Revenue Trends in 3Q17

    Gilead’s revenue Gilead Sciences (GILD) reported revenue of $6.5 billion in 3Q17, a 13% fall from the revenue of $7.5 billion seen in 3Q16. The 3Q17 figure includes product revenue of $6.4 billion, and royalty, contract, and other revenue of $110 million. Analysts expect revenue to fall ~21.9% to $5.7 billion in 4Q17. Geographical sales The above […]

    By Mike Benson
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Analyst Recommendations for Alexion in December 2017

    Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”

    By Daniel Collins
  • uploads///Analysts rating
    Earnings Report

    Analyst Recommendations for Vertex Pharmaceuticals in October

    After 3Q17, Vertex Pharmaceuticals (VRTX) increased its guidance for cystic fibrosis product revenues, from $1.87 billion–$2.1 billion to $2.10 billion–$2.15 billion.

    By Daniel Collins
  • uploads///Analysts Rating
    Earnings Report

    Analysts’ Recommendations for Biogen in October 2017

    Recent developments In October 2017, Biogen (BIIB) and Eisai expanded their existing agreement on the joint development and commercialization of Alzheimer’s disease therapies under investigation. According to the terms of the agreement, Eisai has the option to co-develop and co-commercialize Biogen’s aducanumab for the treatment of Alzheimer’s disease patients. The present expansion of the agreement […]

    By Daniel Collins
  • uploads///BioMarins Developmental
    Company & Industry Overviews

    BioMarin’s Strong Pipeline Could Be a Long-Term Growth Driver

    After success in the company’s phase 1/2 trial with BMN 270, an investigational gene therapy for hemophilia A, BioMarin Pharmaceuticals (BMRN) is expected to start phase 3 trials.

    By Daniel Collins
  • uploads///BioMarin product
    Company & Industry Overviews

    How Did BioMarin Pharmaceuticals’ Drugs Perform in 1H17?

    In 2Q17, BioMarin Pharmaceuticals’ (BMRN) Aldurazyme generated revenues of around $20 million, which was a ~6% increase on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Defitelio
    Company & Industry Overviews

    How Is Jazz’s Defitelio Positioned after 2Q17?

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Acadia Pharmaceuticals in September

    Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”

    By Margaret Patrick
  • uploads///Clinical trial
    Company & Industry Overviews

    This Part of Bioverativ’s Pipeline Could Be a Major Long-Term Growth Driver

    In June 2017, the FDA accepted Bioverativ’s investigative new drug application for BIVV001, a drug designed to treat prophylaxis from bleeding associated with hemophilia A.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Behind Bioverativ’s Analyst Recommendations This September

    Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”

    By Daniel Collins
  • uploads///Orkambi Kalydeco
    Company & Industry Overviews

    How Are Orkambi and Kalydeco Positioned after 2Q17?

    In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Understanding Incyte’s 2Q17 Revenue Stream

    Incyte’s 2Q17 revenue growth was driven by the increased demand for Jakafi.

    By Mike Benson
  • uploads///Chart  BIIB
    Miscellaneous

    What Drove Biogen Stock in 2Q17?

    Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Chart  AMGN
    Miscellaneous

    The Rise of Amgen Stock in 2Q17

    Amgen (AMGN) stock has risen ~5.8% in 2Q17, while it has risen ~17.4% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Analysts Recommendations
    Company & Industry Overviews

    What Analysts Recommend for BioMarin Pharmaceuticals

    A total of 20 analysts were analyzing BioMarin Pharmaceuticals in July 2017. Six analysts recommended a “strong buy,” while nine analysts suggested a “buy.”

    By Daniel Collins
  • uploads///Naglazyme Aldurazyme revenues
    Company & Industry Overviews

    BioMarin Expects These Drugs to Generate Steady Revenues

    In 2016, BioMarin Pharmaceuticals’ (BMRN) Naglazyme generated revenues of around $297 million, a ~2% year-over-year (or YoY) decline.

    By Daniel Collins
  • uploads///Kuvan Revenues
    Company & Industry Overviews

    Kuvan Could Boost BioMarin’s Revenue Growth in 2017

    In 2016, BioMarin Pharmaceuticals’ (BMRN) Kuvan reported revenues of around $348 million, a ~45% year-over-year (or YoY) increase.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Developments for Ionis Pharmaceuticals after 1Q17

    Ionis’s recent developments As discussed earlier, Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or no therapeutic options. Corporate developments In April 2017, Ionis entered into a collaborative agreement with Suzhou Ribo Life Science for the development and commercialization of RNA[1.ribonucleic acid]-targeted therapeutics in China. In […]

    By Mike Benson
  • uploads///Analysts Rating
    Company & Industry Overviews

    Analysts’ Views on Alexion Pharmaceuticals and Its Peers

    Of the 21 analysts analyzing Alexion Pharmaceuticals, six analysts recommended a “strong buy” and 11 analysts recommended a “buy.”

    By Daniel Collins
  • uploads///Strensiq Revenues
    Company & Industry Overviews

    Strensiq: Key Growth Driver for Alexion Pharmaceuticals in 2017

    In 1Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenue of ~$74 million, which reflects ~4% quarter-over-quarter and ~124% YoY growth.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.